8-K: Lifeward Completes Oratech Acquisition, Expands Board

Lifeward Ltd. announced the completion of its acquisition of Oratech Pharma, Inc., alongside significant board changes and equity issuance.

Summary

• Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc., a wholly-owned subsidiary of Oramed Pharmaceuticals, Inc., which was subsequently assigned to Oratech Ltd.
• As consideration for the acquisition, Lifeward issued 2,256,476 ordinary shares and pre-funded warrants to purchase ordinary shares.
• Lifeward also issued 1,296,296 warrants to purchase ordinary shares (Transaction Warrants) to Oramed Pharmaceuticals, Inc. as additional consideration.
• The company agreed to pay Oramed certain quarterly revenue sharing payments based on sales of its ReWalk Personal Exoskeleton products and related extended warranties.
• Lifeward issued $10,000,000.00 aggregate principal amount senior secured convertible notes and accompanying warrants to Oramed and certain investors in an unregistered sale.
• Dr. John William Poduska and Randel Richner resigned from Lifeward's Board of Directors, effective March 25, 2026.
• Nadav Kidron, Miriam Kidron, Ph.D., and Yehuda Reznick were appointed as new directors, expanding the Board from five to eight members, effective March 25, 2026.
• The Audit, Compensation, and Nominating and Corporate Governance Committees were reconstituted with the new board members.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting strategic expansion through acquisition and successful capital raising, though tempered by potential shareholder dilution from the equity and warrant issuances.

Positives

• Completion of the strategic acquisition of Oratech Pharma, potentially expanding Lifeward's product portfolio and market reach.
• Successful capital raise of $10,000,000.00 through senior secured convertible notes and accompanying warrants, providing funding for the acquisition and operations.
• Expansion of the Board of Directors with three new members, potentially bringing diverse expertise and strengthening corporate governance.

Negatives

• Issuance of 2,256,476 ordinary shares, pre-funded warrants, and 1,296,296 transaction warrants as acquisition consideration, which could lead to shareholder dilution.
• Agreement to pay Oramed quarterly revenue sharing payments based on ReWalk Personal Exoskeleton sales, which will impact future revenue streams from these products.
• Potential future dilution from the conversion of the $10,000,000.00 senior secured convertible notes and the exercise of accompanying warrants.

Risks

• Shareholder dilution risk due to the issuance of 2,256,476 ordinary shares, pre-funded warrants, and 1,296,296 transaction warrants as part of the acquisition.
• Further dilution risk from the potential conversion of the $10,000,000.00 senior secured convertible notes and the exercise of accompanying warrants issued to investors.
• The equity securities issued were not registered under the Securities Act or any state securities laws, limiting their immediate resale in the United States without registration or an applicable exemption.

Future Outlook

Lifeward has committed to paying Oramed Pharmaceuticals, Inc. certain quarterly revenue sharing payments based on future sales of its ReWalk Personal Exoskeleton products and related extended warranties, indicating a long-term financial obligation tied to product performance.

Management Comments

• The Company extends its deepest gratitude to Dr. Poduska and Ms. Richner for their distinguished service to the Board and lasting contributions to the Company.

Industry Context

StockSavvy.ai notes that the acquisition of Oratech Pharma by Lifeward, a company primarily known for its ReWalk exoskeletons, suggests a strategic move to potentially diversify or strengthen its medical device portfolio. The use of equity and convertible notes for financing is a common approach for growth-oriented companies in the medical technology sector to fund expansion and acquisitions, reflecting a dynamic M&A environment.

Comparison to Industry Standards

• The financing structure, involving both equity issuance and convertible debt, is a standard mechanism for funding strategic acquisitions in the biotech and medical device industries, comparable to how smaller, innovative companies are often integrated by larger players like Zimmer Biomet or Stryker.
• The inclusion of revenue-sharing payments as part of the acquisition consideration aligns seller incentives with the acquired asset's future performance, a common practice in deals involving emerging technologies or products with uncertain future revenue streams.
• The expansion of the board and reconstitution of committees are typical post-acquisition corporate governance adjustments, ensuring appropriate oversight and integration of new strategic directions, similar to best practices observed across publicly traded companies after significant M&A events.

Management Changes

Corporate Governance

Related Party Transactions

• Oramed Pharmaceuticals, Inc. received 2,256,476 ordinary shares, pre-funded warrants, and 1,296,296 transaction warrants as consideration for the acquisition of its subsidiary, Oratech Pharma, Inc.
• Oramed Pharmaceuticals, Inc. also received $10,000,000.00 in senior secured convertible notes and accompanying warrants as an investor in Lifeward's capital raise.
• Lifeward agreed to pay Oramed Pharmaceuticals, Inc. quarterly revenue sharing payments based on sales of ReWalk Personal Exoskeleton products and related extended warranties.
• Nadav Kidron, who is the Chief Executive Officer of Oramed Pharmaceuticals Inc., was appointed as a Class III director of Lifeward Ltd.

Stakeholder Impact

• **Shareholders:** Face potential dilution from the issuance of new ordinary shares, pre-funded warrants, and transaction warrants for the acquisition, as well as from the conversion of senior secured convertible notes and exercise of accompanying warrants.
• **Oramed Pharmaceuticals, Inc.:** Becomes a significant shareholder and creditor of Lifeward, and will receive future revenue sharing payments, aligning its interests with Lifeward's ReWalk product success.
• **Oratech Employees/Management:** Will be integrated into Lifeward's organizational structure, potentially leading to operational changes.
• **Customers (ReWalk Personal Exoskeleton):** No direct immediate impact mentioned, but the revenue sharing agreement could incentivize continued focus and investment in these products.

Next Steps

• Integration of Oratech Ltd. into Lifeward's operations following the completion of the acquisition.
• Ongoing payment of quarterly revenue sharing payments to Oramed Pharmaceuticals, Inc. based on sales of ReWalk Personal Exoskeleton products and related extended warranties.
• New directors will be entitled to standard compensation available to non-employee directors of the Company.

Key Dates

Recommendation

The completion of the Oratech acquisition and the associated capital raise provide strategic growth opportunities for Lifeward. However, the significant equity issuance and potential future dilution from warrants and convertible notes introduce a degree of uncertainty for existing shareholders. The board changes, while expanding expertise, are a standard part of such transactions. Given the mixed implications of growth potential versus dilution, a 'hold' recommendation is appropriate until further clarity on integration synergies and financial performance post-acquisition emerges.

Keywords

Lifeward Ltd., Oratech Pharma, Acquisition, Merger, SEC 8-K, Equity Issuance, Convertible Notes, Board Changes, Corporate Governance, LFWD, Oramed Pharmaceuticals, ReWalk Exoskeleton